BeiGene USA, Inc.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With over 2,200 employees in China, the U.S., Australia and Europe, BeiGene is advancing a pipeline of novel oral small molecules and monoclonal antibodies. BeiGene is also working to create combination solutions aimed to have a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.